SAMP8 mice exhibit changes that commonly occur with normal aging late in life, but do so at a much earlier age. These changes include impairments in learning and memory as early as 8 months of age and so the SAMP8 is a useful model to investigate those age-related brain changes that may affect cognition. As brain insulin signaling and memory decline with aging, the SAMP8 model is useful for investigating these changes and interventions that might prevent the decline. This review will summarize the SAMP8 mouse model, highlight changes in brain insulin signaling and its role in memory, and discuss intranasal insulin delivery in investigating effects on insulin metabolism and memory in the SAMP8 mice.
Introduction
Senescence accelerated mice (SAM) were first developed and described by the lab of Toshio Takeda in 1981 (Takeda et al., 1981) . Selective breeding led to the SAMP8 line after observing memory and cognitive deficits. SAMP8 mice have normal development but have strain-specific characteristics of rapid aging such as hair loss, circadian rhythm disruptions, and a shortened median lifespan reported to be anywhere from 10 to 17.2 months (Flood and Morley, 1998) . The spontaneous loss of memory can occur as early as 8 months of age (Miyamoto et al., 1986) , with severe cognitive deficits by 12 months. SAMP8 mice are a model of sporadic Alzheimer's disease (AD), displaying features that occur early in the pathogenesis of AD, including cortical atrophy, neuronal cell loss, gliosis, oxidative stress, increased brain levels of amyloid-β peptide (Aβ), tau phosphorylation changes, and deficits in learning and memory (Morley et al., 2012b) .
Age-associated memory impairment has been theorized to be caused by defects in hippocampal synaptic plasticity, peripheral inflammation, and oxidative stress. Insulin is involved in each of these processes. Furthermore, insulin has been shown to improve memory in young adults (Benedict et al., 2004 ), Alzheimer's patients , and SAMP8 mice .
Role for insulin signaling in aging and memory
Insulin readily crosses the blood-brain barrier (BBB) and activates insulin receptors in the brain, which are widely expressed on many cell types. Insulin signaling in the brain elicits changes in feeding behavior and in learning and memory. Insulin receptor levels are highest in the hypothalamus and cerebral cortex in humans (Hopkins and Williams, 1997) , while in rodents the highest levels are in the olfactory bulb and hippocampus, the latter a fundamental site for the acquisition, consolidation, and recollection of information (Marks et al., 1990) . Insulin binding to its receptor induces phosphorylation of the receptor, leading to activation of the insulin signaling pathways through phosphorylation of AKT or mitogen activated protein kinase (MAPK). Activation of insulin signaling has neuromodulatory effects, and contributes to a variety of neurobiological processes such as synaptogenesis, nerve growth, and Aβ clearance from the brain . Alterations in brain insulin signaling are thought to contribute to neurodegenerative diseases, such as AD (Meredith et al., 2015) . With age and in patients with AD, there is decreased brain insulin receptor sensitivity and expression as well as decreased phosphorylation of the insulin receptor and downstream substrates (Frolich et al., 1998; Talbot et al., 2012) . These alterations result in an insulin-resistant state in the brain.
Even though activation of the insulin signaling cascade has beneficial effects, inhibition of this pathway throughout the body is considered an evolutionarily conserved mechanism for extending lifespan (Kenyon, 2005) . Klotho is an aging suppressor protein that can extend lifespan when overexpressed (Kuro-o, 2011) . It prevents or reverses tyrosine phosphorylation of the insulin receptor and is therefore considered an inhibitor of the insulin signaling pathway (Kurosu et al., 2005) . Klotho mRNA has been detected in high levels in mouse hippocampus (Nagai et al., 2003) . Widespread loss of klotho results in memory impairments and increased oxidative stress in the brain (Nagai et al., 2003) . As oxidative stress increases with age, as exhibited by the SAMP8 mice (Morley et al., 2012a) , and has been linked to AD (Christen, 2000) , investigating mediators of oxidative stress in the brain might help delay age-related memory impairments.
Maintenance of insulin sensitivity in peripheral tissues is a predictor of longevity in humans (Barbieri et al., 2008) . Understanding the changes that take place in brain insulin signaling during aging and in diseases such as AD will help in alleviating some of the cognitive deficits. Recent work indicates that the SAMP8 mouse has impaired insulin signaling in the central nervous system (CNS), and therefore may be an important model for studying the role of insulin in AD. The remainder of this review will discuss current knowledge of pathological changes in insulin signaling and pharmacological interventions that target the insulin signaling pathway to improve cognition in the SAMP8 mouse.
Central insulin signaling and memory in the SAMP8 mice
To date, a total of 8 articles have been published on the role of insulin in the CNS of SAMP8 mice, with 7 being published within the last 3 years ( Table 1 ). The first of these studies was published in 2000 by Banks et al., investigating whether SAMP8 mice had BBB disruptions and/or alterations in insulin transport across the BBB (Banks et al., 2000) . Previous reports had suggested the BBB may be impaired in AD. Banks et al. found a decrease in the weight of the frontal cortex in the aged SAMP8 mice despite an 8% increase in total brain weight of aged male SAMP8 mice compared to young SAMP8 mice. This loss of cortical volume could be related to the deficits in learning and memory observed in this mouse model. There was no disruption of the BBB in aged SAMP8 mice as measured with the serum marker albumin. In addition, there was no change in the kinetics of insulin transport across the BBB in the whole brain of aged SAMP8 mice. Therefore, aging of SAMP8 mice does not affect the permeability of the BBB as measured by albumin or the ability of peripheral insulin to access the brain.
A series of studies investigating the effects of compounds found in healing Chinese herbal medicines on central insulin metabolism and cognition then followed. Six-month old male SAMP8 mice were used to study the effects of a daily 3-month oral treatment of asiaticoside (40 or 80 mg/kg/day) on learning and spatial memory (Lin et al., 2013) . Asiaticoside treatment significantly improved memory as measured by escape latency and passive avoidance compared to untreated SAMP8 mice. Oxidative stress and Aβ 1-42 protein levels were decreased with treatment. Asiaticoside treated SAMP8 animals had increased expression of proteins important in synaptic plasticity as well as increased levels of insulin degrading enzyme (IDE) mRNA levels. Aβ 1-42 is also a substrate for IDE. The preservation of IDE levels could be responsible for the decrease in Aβ 1-42 levels. However, whether or not CNS insulin levels were altered with asiaticoside treatment was not investigated. The increase in acetylcholine esterase activity observed with age did not occur with asiaticoside treatment, suggesting a preservation of the cholinergics which are important in memory formation. In all, this compound was able to ameliorate some of the age-related deficits that occur in the SAMP8 mouse by 9 months of age.
Ligustilide is the main lipophilic constituent of Umbelliferae medicinal plants. Ten-month old male SAMP8 mice were treated by oral gavage with 10 or 40 mg/kg/day for 8 weeks (Kuang et al., 2014) . Ligustilide improved memory deficits in aged SAMP8 mice as measured by passive avoidance and Y-maze alteration. The number of senescent cells was increased with age in the hippocampus and cerebral cortex of SAMP8 mice, but ligustilide prevented this increase. Ligustilide reduced accumulation of changes in AD-associated proteins including Aβ 1-42 and tau phosphorylation levels, while also preventing neuronal loss in aged SAMP8 mice. Ligustilide decreased oxidative stress as well as increasing the resistance towards oxidative stress. Concomitantly, ligustilide prevented the decreased expression of klotho found in the aged SAMP8 mice. It is unclear how ligustilide might regulate klotho expression levels. Ligustilide did increase forkhead box O1 (FoxO1) activation which could be a reason why oxidative stress was decreased with treatment. FOXO1 activation allows this transcription factor to remain in the nucleus, altering the regulation many genes involved in cell survival and differentiation and mediate oxidative stress (Akintola and van Heemst, 2015) . While FOXO1 protein levels are decreased in the liver and pancreas of aged SAMP8 mice (Tomobe et al., 2013; Tresguerres et al., 2013) , FOXO1 reactivity or expression levels in brain have not been measured in the aged SAMP8 mouse. FOXO proteins are considered some of the most important transcriptional effectors of the insulin signaling pathway (Martins et al., 2016) . Insulin pathway activation causes phosphorylation of FOXO1, excluding it from the nucleus (Martins et al., 2016) .
Tetrahydroxystilbene glucoside (TSG) is a main component of the Polygonaceae plant, Polygonatum multiflorum, and may have lifespan extending properties (Zhou et al., 2015) . In order to determine how TSG might extend lifespan, SAMP8 mice were treated with 2, 20, and 50 mM TSG each day. SAMP8 survival was improved in the TSG-treated group by about 17% in the 20 mM group. TSG improved SAMP8 memory as measured by the Morris water maze. Klotho protein levels and phosphorylation of AKT was increased in the cortex of TSG-treated mice. Indeed, TSG reduced the amount of insulin, insulin receptor, insulin-like growth factor 1 (IGF-1), and IGF-1 receptor in the cortex. Peripheral perturbations in these individual mediators of the insulin signaling pathway are associated with increased longevity (Kenyon, 2005) .
Amylin is a regulatory satiety peptide that is co-secreted with insulin by the pancreas. It crosses the BBB three times faster and the percent of injected dose/g of brain is more than two-fold greater than insulin (Banks and Kastin, 1998) . In the CNS, amylin can activate proteins in the insulin signaling cascade, including Akt and MAPK (Moon et al., 2011) . Circulating amylin levels are reduced in plasma of human subjects with mild cognitive impairment and AD (Adler et al., 2014) . Pramlintide, an amylin analog, was constantly infused via an osmotic mini-pump with 0.24 mg/kg/day for 5 weeks in 6-month old SAMP8 mice (Adler et al., 2014) . Pramlintide treated SAMP8 mice had improved memory as measured by the object recognition test. The hippocampus had decreased levels of oxidative stress markers and increased expression levels of proteins involved in synaptic function when treated with pramlintide. The improvement in synaptic function could be related to the reversal of age-related decline in memory observed in the SAMP8 mouse. Although direct changes in the insulin signaling pathway were not investigated in this study, previous studies have shown CNS-specific Table 1 Review of current literature in chronological order on the changes in memory and insulin signaling with various treatments in SAMP8 mice. Other than memory improvements with treatment, molecular key findings related to insulin are listed. increases in AKT phosphorylation with amylin treatment (Moon et al., 2012) . Aβ protein precursor (AβPP) levels are increased in aged SAMP8 mice . 12-month old SAMP8 mice were treated with 3 doses of 6 μg oligonucleotide (random or AβPP antisense) via tail vein injection spaced 2 weeks apart (Armbrecht et al., 2015) . The antisense crosses the BBB (Banks et al., 2001 ) and this treatment paradigm has been shown to decrease AβPP and Aβ levels . Memory, as measured in the T maze, was improved with antisense treatment. Antisense treatment changed expression of 944 genes in key pathways including phosphatidylinositol signaling and MAPK signaling. Changes in these pathways contributed to changes in neurotropin signaling, insulin signaling and ErbB signaling. There were 20 genes specifically changed in the insulin signaling pathway with antisense treatment. Therefore, it is possible that alterations in genes involved in insulin signaling contribute to the memory improvements observed in the aged SAMP8 mouse.
Caloric restriction mimetics and inhibitors of α-glucosidase have been investigated as ways to delay aging. Acarbose is one such mimetic and helps control blood glucose levels by slowing the metabolism of sugars. Long-term administration of acarbose delays age-associated diseases and can reverse brain aging. Three-month old SAMP8 mice received 20 mg/kg/day dissolved in drinking water until 9 months of age Yan et al., 2015) . Serum insulin was decreased in aged SAMP8 mice while acarbose prevented this decrease and improved memory, sensorimotor skills, and anxiety as assessed by multiple behavior tests. Acarbose increased levels of insulin receptors in the hippocampus as well as histone H4 lysine 8 (H4K8) acetylation levels. Acetylation of H4K8 can be modulated by IGF-1 (Sun and D'Ercole, 2006) , regulates brain-derived neurotrophic factor (BDNF) expression, and enhances learning and memory (Intlekofer et al., 2013) . Aged SAMP8 mice had decreased BDNF levels in the hippocampus, which correlated with poor performance on the Morris water maze. Acarbose reversed the age-related decline in BDNF. These results show acarbose can alleviate the declines in insulin signaling, preserving memory by maintaining BDNF levels and acetylation of H4K8.
The effects of another inhibitor of α-glucosidase, 1-deoxynojirimycin (DNJ), was investigated by the same group in aged SAMP8 mice (10 or 20 mg/kg/day) from 3 to 9 months of age . Similar results were observed in that chronic DNJ treatment alleviated age-related changes in the SAMP8 mice including the decreased level in serum insulin and hippocampal levels of the insulin receptor, BDNF, and H4K8 acetylation and the increased level of astrocyte activation. Taken together, the acarbose and DNJ studies suggest an important role for α-glucosidase in aging and dysregulation of insulin signaling.
These studies characterize important changes taking place in the brain of aged SAMP8 mice (Table 2 ) and support the idea that maintaining CNS insulin signaling can lead to improved memory and in one instance, increase lifespan. Importantly, none of these studies investigated direct administration of the agents to the CNS, but rather relied on transport to the brain or peripheral administration of the compounds. Whether the beneficial effect of these treatments is due to alterations in insulin signaling or an independent mechanism of insulin remains to be determined.
Intranasal delivery
Intranasal delivery was popularized by William H. Frey in the early 1990's as a noninvasive route to bypass the BBB and deliver substrates directly to the brain (Schioth et al., 2012) . Because blood levels of the therapeutic are low, side effects mediated by peripheral tissues are reduced. The central versus peripheral effects of insulin on the effect of memory and insulin signaling in the CNS have been parsed out using the intracerebroventricular (ICV) delivery method (Schioth et al., 2012) . However, ICV delivery is not a practical, translatable route of delivery of insulin to the brain.
Intranasal delivery of peptides and proteins is proving to be a viable alternative to increase brain levels of therapeutic compounds. After intranasal administration to the level of the cribriform plate, substrates can enter the CNS via olfactory and trigeminal neural pathways (Hanson and Frey, 2008) . Concentrations in brain of delivered substrates after intranasal administration are often similar to those delivered intravenously. For example, approximately 0.05% Inj/g-brain of the insulin dose delivered intravenously reaches the brain (Banks et al., 1997) , whereas after intranasal delivery, approximately 0.1% Inj/gbrain of the insulin dose is delivered to the brain . However, the amount of the compound in blood after intranasal administration is often only a fraction of that seen after intravenous administration, thus reducing peripheral tissue exposure. Degradation that can occur in the circulation or in the brain after intranasal delivery can vary for each peptide, protein, or substrate of interest.
Intranasal delivery of various proteins and peptides including glucagon-like peptide 1, leptin, pituitary adenylate cyclase-activating peptide, and insulin have been shown to have beneficial effects on memory (Meredith et al., 2015) . Some of these treatments, including intranasal insulin, are currently being investigated in ongoing clinical studies investigating enhancement of memory.
Intranasal insulin delivery
Intranasal insulin administration is an effective therapeutic treatment for improving memory. Not only does it improve memory in populations that have decreased insulin signaling to begin with, such as patients with AD or mild cognitive impairment Reger et al., 2008) , but memory is also enhanced in healthy, young populations (Benedict et al., 2004) . Improvements in people with AD are observed as early as 15 min after the first treatment (Reger et al., 2008) and continue after chronic, daily treatment for up to 4 months . The Study of Nasal Insulin to Fight Forgetfulness (SNIFF) is a clinical trial currently being conducted in the United States to more fully investigate the long-term benefit of intranasal insulin.
In order to determine how intranasal insulin might enhance memory, the SAMP8 model of age-related memory impairment has been used to investigate memory and biochemical changes taking place after administration. Indeed, memory was improved 24 h after a single or repetitive 1 μg treatment in aged SAMP8 mice . In a young, healthy CD-1 mouse cohort, intranasal insulin had no effect on peripheral metabolism or blood glucose levels. Within 5 min after administration, insulin was detected throughout the brain with levels being greatest in the hypothalamus N olfactory bulb N hippocampus N cerebellum N cortex (Fig. 1) . These studies showing similar memory enhancing effects in the SAMP8 mice as observed in the clinical studies argue for continuation in investigation of pathways altered in the brains of SAMP8 mice after intranasal insulin administration.
Conclusions
The studies highlighted here using the SAMP8 mouse support the involvement of the insulin signaling pathway in the improvement of memory. Dysregulation of brain insulin signaling is detrimental to cognition and can increase the risk of age-related disorders (Gerozissis, 2008; Ghasemi et al., 2013) . The klotho studies show that inhibiting the insulin pathway in the CNS leads to an increased lifespan and improved cognition, while the majority of the other treatments presented here support increasing brain insulin levels to enhance memory. Therefore, it appears there is a hormetic effect of insulin in the brain where too much insulin signaling can lead to overactivation and advanced aging, but too little insulin signaling impairs cognition. Maintaining a proper balance of CNS insulin signaling with aging seems crucial in preserving memory.
Indeed, using the intranasal delivery route in the SAMP8 mice for the compounds and peptides summarized in this review could better target the central effects of insulin signaling. In addition, the SAMP8 model could prove useful for studying the anti-aging effects of many compounds currently being investigated in the periphery that have also been shown to enhance memory including rapamycin (Halloran et al., 2012) , resveratrol (Porquet et al., 2013) , and alpha-lipoic acid (Farr et al., 2003) .
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